Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
+0.53 (9.87%)
Oct 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.21 - 5.97
52 week 4.26 - 11.15
Open 5.27
Vol / Avg. 0.00/1.06M
Mkt cap 411.14M
P/E 106.69
Div/yield     -
EPS 0.06
Shares 69.68M
Beta 1.81
Inst. own 98%
Nov 5, 2015
Q3 2015 Progenics Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Oct 1, 2015
Progenics Pharmaceuticals Inc Research and Development Day
Aug 6, 2015
Q2 2015 Progenics Pharmaceuticals Inc Earnings Release
Aug 6, 2015
Q2 2015 Progenics Pharmaceuticals Inc Earnings Call - Webcast
Jul 8, 2015
Progenics Pharmaceuticals Inc at Cantor Fitzgerald Inaugural Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -603.87% 9.94%
Operating margin -604.44% 7.59%
EBITD margin - 14.85%
Return on average assets -32.02% 3.20%
Return on average equity -42.50% 4.33%
Employees 57 -
CDP Score - -


777 Old Saw Mill River Rd
TARRYTOWN, NY 10591-6717
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 62
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 58
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 50
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Michael D. Kishbauch Independent Director
Age: 66
Bio & Compensation  - Reuters
David A. Scheinberg MD., Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Nicole S. Williams Independent Director
Age: 70
Bio & Compensation  - Reuters